story of the week
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
J. Clin. Oncol 2020 Sep 18;[EPub Ahead of Print], AMM Eggermont, CU Blank, M Mandala, GV Long, VG Atkinson, S Dalle, AM Haydon, A Meshcheryakov, A Khattak, MS Carlino, S Sandhu, J Larkin, S Puig, PA Ascierto, P Rutkowski, D Schadendorf, R Koornstra, L Hernandez-Aya, AM Di Giacomo, AJM van den Eertwegh, JJ Grob, R Gutzmer, R Jamal, PC Lorigan, ACJ van Akkooi, C Krepler, N Ibrahim, S Marreaud, M Kicinski, S Suciu, C RobertFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.